2 weeks Ago By ABMN Staff
Russell Investments Group Ltd. trimmed its position in shares of Dyne Therapeutics, Inc. ( NASDAQ:DYN – Free Report ) by 5.
5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 116,729 shares of the company’s stock after selling 6,735 shares during the period. Russell Investments Group Ltd.
’s holdings in Dyne Therapeutics were worth $2,750,000 as of its most recent SEC filing. Other large investors have also made changes to their positions in the company. KBC Group NV lifted its position in shares of Dyne Therapeutics by 45.
3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after buying an additional 978 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in Dyne Therapeutics during the fourth quarter valued at approximately $257,000.
Magnetar Financial LLC bought a new position in shares of Dyne Therapeutics in the fourth quarter valued at approximately $263,000. E Fund Management Co. Ltd.
lifted its stake in shares of Dyne Therapeutics by 11.8% in the fourth quarter. E Fund Management Co.
Ltd. now owns 11,848 shares of the company’s stock worth $279,000 after buying an additional 1,249 shares during the last quarter. Finally, Legato Capital Management LLC bought a new stake in shares of Dyne Therapeutics during the 4th quarter worth $305,000.
Institutional investors own 96.68% of the company’s stock. Insider Activity at Dyne Therapeutics In other news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, February 18th.
The shares were sold at an average price of $13.95, for a total value of $36,242.10.
Following the completion of the transaction, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. The trade was a 1.
29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link . Insiders sold 6,237 shares of company stock valued at $77,760 in the last ninety days.
Insiders own 20.77% of the company’s stock. Wall Street Analysts Forecast Growth Check Out Our Latest Research Report on DYN Dyne Therapeutics Price Performance Dyne Therapeutics stock opened at $8.
17 on Friday. The business has a 50 day simple moving average of $11.24 and a 200 day simple moving average of $20.
69. The company has a market capitalization of $924.20 million, a PE ratio of -2.
29 and a beta of 1.21. Dyne Therapeutics, Inc.
has a one year low of $6.36 and a one year high of $47.45.
Dyne Therapeutics ( NASDAQ:DYN – Get Free Report ) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.
92) by $0.04. Equities analysts anticipate that Dyne Therapeutics, Inc.
will post -3.44 earnings per share for the current fiscal year. About Dyne Therapeutics ( Free Report ) Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.
It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Featured Articles Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc.
( NASDAQ:DYN – Free Report ). Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
